Ocuphire Pharma Inc. (OCUP)

The total asset value of Ocuphire Pharma Inc. (OCUP) stood at $ 50 Mln as on 31-Mar-23

The share price of Ocuphire Pharma Inc. (OCUP) is $2.71 (NASDAQ) as of 28-Nov-2023 16:00 EST. Ocuphire Pharma Inc. (OCUP) has given a return of -25.6% in the last 3 years.

Ocuphire Pharma Inc. (OCUP) has a market capitalisation of $ 79 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Ocuphire Pharma Inc. (OCUP) is 5.40 times as on 09-Jun-2023, a 1.13% premium to its peers’ median range of 2.54 times.

The P/E (price to earnings) ratio of Ocuphire Pharma Inc. (OCUP) is 4.09 times as on 09-Jun-2023.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ocuphire Pharma Inc. (OCUP) and enter the required number of quantities and click on buy to purchase the shares of Ocuphire Pharma Inc. (OCUP).

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

The CEO & director of Ms. Mina Patel Sooch M.B.A., MBA. is Ocuphire Pharma Inc. (OCUP), and CFO & Sr. VP is Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc.

The promoters of Ocuphire Pharma Inc. (OCUP) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Ocuphire Pharma Inc. (OCUP) was $-15 Mln.